By Evelyn Schulz & Susann Jahn | Noerr  Following our article “Brexit with or without a deal: Consequences for pharmaceutical companies”, which provided a general overview of the challenges facing pharmaceutical companies, this article deals specifically with the impact of Brexit on medicinal product marketing authorisations. Whether there will be a Brexit with or without a deal is of secondary importance with regard to medicinal product marketing authorisations – this question primarily determines the period within which pharmaceutical companies will be confronted with the...

Read more

By Kevin Butler| Managing Director Ireland and the United Kingdom | TMF Group  We’re fielding three common questions about Brexit from concerned businesses in the UK and Europe. But it’s the questions they’re not asking that are most pressing. A no-deal Brexit is firming up as a real possibility as political wrangling over the UK’s exit from the EU continues. While a comprehensive withdrawal agreement – or even a called-off Brexit – remain the ideal outcomes for business, making the necessary preparations...

Read more